The CXCR4 antagonist could effectively reverse MSC-mediated drug resistance and sensitize leukemic cells from refractory/relapsed ALL patients to chemotherapy drugs [61]. The gene discussed is CXCR4; the disease is acute lymphoblastic leukemia.